Our breakthrough, proprietary technology platform engineered to enhance drug absorption
End-to-end, in-house control of formulation, development, and manufacturing capabilities
Our proprietary cannabinoid composition for the management of pain and inflammation
Partnering with the world’s leading research institutions and doctors to support FDA-authorized investigator-initiated clinical trials
Learn more about cannabidiol from the medical community and regulators
We are modernizing the way medicines are taken
Experts in drug development and delivery, manufacturing, and commercialization
Recent media coverage regarding Orcosa
Company news and announcements
July 14, 2022
EWING, N.J.–(BUSINESS WIRE)–Orcosa Inc. (“Orcosa” or the “Company”), a clinical-stage life sciences company improving patient outcomes through its next generation drug delivery technology – the Rapid Infusion Technology (RITe™) Platform – today announced the appointment of Dr. Andrew C. von Eschenbach, former Commissioner of the U.S. Food and Drug Administration (“FDA”) as Senior Advisor. In his role, Dr. von Eschenbach will provide strategic counsel on regulatory and public affairs, clinical trial development, and other corporate matters.
“We are honored and privileged to have Dr. von Eschenbach join our team as Senior Advisor,” said Bryan Ridall, President of Orcosa. “His commitment to improving public health, and his uniquely complete understanding of patients’ needs, and the dynamics of biopharmaceutical research and development are an invaluable complement to our leadership team. We are grateful for his support as we continue to execute on our long-term strategy.”
Dr. von Eschenbach said, “As a physician and former FDA Commissioner, I was immediately impressed with Orcosa’s innovative drug delivery platform and thoughtful approach to clinical development and collaboration. The company’s RITe platform is already demonstrating how it has incredible potential to improve patient outcomes across a range of therapeutic areas – including most critically, in pain management to help reduce opioid usage. I am excited to be part of the Orcosa team, particularly at such a pivotal time in the company’s growth story.”
Dr. von Eschenbach is widely recognized as a leading physician, surgeon, oncologist, and executive, and served as Commissioner of the FDA from 2006 to 2009, after being appointed Acting Commissioner in 2005. In that role, he developed and oversaw the FDA’s Critical Path Initiative which aimed at improving the regulatory pathway for drugs and medical devices. Dr. von Eschenbach joined FDA after serving for four years as Director of the National Cancer Institute at the National Institutes of Health, and currently serves on the Board of Directors of the Reagan-Udall Foundation for the Food and Drug Administration.
Dr. von Eschenbach earned a B.S. from St. Joseph’s University and his medical degree from Georgetown University School of Medicine. After completing a residency in urologic surgery at Pennsylvania Hospital in Philadelphia, he was an instructor in urology at the University of Pennsylvania School of Medicine. He completed a Fellowship in Urologic Oncology at the University of Texas M.D. Anderson Cancer Center.
About Orcosa Inc.Orcosa Inc. is a life sciences company modernizing the way medicines are taken and improving patient outcomes through its proprietary therapeutic delivery technology, the Rapid Infusion Technology (RITe™) Platform. Orcosa is the inventor, developer and exclusive owner of the RITe™ Platform, a fast acting, easy-to-take tablet engineered to enhance drug absorption. Orcosa’s lead program, ORAVEXX™, is a non-addictive proprietary cannabidiol composition that utilizes the RITe™ Platform to treat pain and has the potential to provide a safe, alternative treatment option to opioids and NSAIDs. The company is currently supporting clinical trials at leading American research institutions to evaluate the safety and effectiveness of ORAVEXX™ for pain management. For more information on Orcosa, please visit https://www.orcosa.com.
Forward-Looking StatementsCertain statements made herein constitute “forward-looking statements”. These forward-looking statements include, but are not limited to, the development of ORAVEXX™ and the RITe™ Platform. These statements are based on the current expectations of Orcosa and are not predictions of actual performance. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Orcosa to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Media Contact:Devin BrodaFGS GlobalDevin.Broda@fgsglobal.com212-687-8080
Investor Contact:IR@orcosa.com